Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics?

Medical Hypotheses

Volumn 81, Issue 1, 2013, Pages 10-14

  Coppola, M ^a   Mondola, R ^b  

^a ASL CN2   (Italy)

^b ASL CN1   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; METHOXYDINE; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OPIATE RECEPTOR; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ALCOHOLISM; ANTIDEPRESSANT ACTIVITY; ARTICLE; DEPRESSION; HUMAN; SUICIDAL IDEATION;

ALCOHOLISM; ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; MODELS, THEORETICAL; PHENCYCLIDINE;

EID: 84878544322     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.03.030     Document Type: Article

References (117)

1. Gilpin N.W., Koob G.F. Neurobiology of alcohol dependence: focus on motivational mechanisms. Alcohol Res Health 2008, 31:185-195.
2. Grant B.F., Dawson D.A., Stinson F.S., et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004, 74:223-234.
3. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Alcohol Alert. 2001. Available on: http://pubs.niaaa.nih.gov/publications/aa51.htm.
4. Rehm J, Shield KD, Rehm MX, et al. Alcohol consumption, alcohol dependence and attributable burden of disease in Europe. Potential gains from effective interventions for alcohol dependence. 2012. Available on: http://www.camh.ca/en/research/news_and_publications/reports_and_books/Documents/CAMH%20Alcohol%20Report%20Europe%202012.pdf.
5. European Medicines Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence. 2010. Available on: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500074898.pdf.
6. World Health Organization. Alcohol. Fact sheet. 2011. Available on: http://www.who.int/mediacentre/factsheets/fs349/en/index.html.
7. Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSMIII-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8-19.
8. Kessler R.C., Crum R.M., Warner L.A., et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997, 54:313-321.
9. Soyka M., Hollweg M., Naber D. [Alcohol dependence and depression. Classification, comorbidity, genetic and neurobiological aspects]. Nervenarzt 1996, 67:896-904.
10. Davidson K.M. Diagnosis of depression in alcohol dependence: changes in prevalence with drinking status. Br J Psychiatry 1995, 166:199-204.
11. Schuckit M.A. Alcohol and depression: a clinical perspective. Acta Psychiatr Scand Suppl 1994, 377:28-32.
12. Kessler R.C., Nelson C.B., Mcgonagle K.A., et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996, 66:17-31.
13. Regier D.A., Farmer M.E., Rae D.S., et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990, 264:2511-2518.
14. Flensborg-Madsen T. Alcohol use disorders and depression-the chicken or the egg?. Addiction 2011, 106:916-918.
15. Boden J.M., Fergusson D.M. Alcohol and depression. Addiction 2011, 106:906-914.
16. Fergusson D.M., Boden J.M., Horwood L.J. Tests of causal links between alcohol abuse or dependence and major depression. Arch Gen Psychiatry 2009, 66:260-266.
17. Dongier M. What are the treatment options for comorbid alcohol abuse and depressive disorders?. J Psychiatry Neurosci 2005, 30:224.
18. Litten R.Z., Allen J.P. Pharmacologic treatment of alcoholics with collateral depression: issues and future directions. Psychopharmacol Bull 1998, 34:107-110.
19. Sher L., Sperling D., Stanley B.H., et al. Triggers for suicidal behavior in depressed older adolescents and young adults: do alcohol use disorders make a difference?. Int J Adolesc Med Health 2007, 19:91-98.
20. Sher L., Oquendo M.A., Galfalvy H.C., et al. The relationship of aggression to suicidal behavior in depressed patients with a history of alcoholism. Addict Behav 2005, 30:1144-1153.
21. Sher L. Alcohol and suicide: neurobiological and clinical aspects. ScientificWorldJournal 2006, 6:700-706.
22. Suter M., Strik W., Moggi F. Depressive symptoms as a predictor of alcohol relapse after residential treatment programs for alcohol use disorder. J Subst Abuse Treat 2011, 41:225-232.
23. Farren C.K. Mc Elroy S. Treatment response of bipolar and unipolar alcoholics to an inpatient dual diagnosis program. J Affect Disord 2008, 106:265-272.
24. Kranzler H.R., Armeli S., Tennen H., et al. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol 2011, 31:22-30.
25. Muhonen L.H., Lahti J., Sinclair D., et al. Treatment of alcohol dependence in patients with co-morbid major depressive disorder-predictors for the outcomes with memantine and escitalopram medication. Subst Abuse Treat Prev Policy 2008, 3:3-20.
26. Hirschtritt M.E., Pagano M.E., Christian K.M., et al. Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders. J Subst Abuse Treat 2012, 42:366-372.
27. Favre J.D., Guelfi-Sozzi C., Delalleau B., et al. Tianeptine and alcohol dependence. Eur Neuropsychopharmacol 1997, 7:S347-S351.
28. Sari Y., Johnson V.R., Weedman J.M. Role of the serotonergic system in alcohol dependence: from animal models to clinics. Prog Mol Biol Transl Sci 2011, 98:401-443.
29. Cornelius J.R., Bukstein O., Salloum I., et al. Alcohol and psychiatric comorbidity. Recent Dev Alcohol 2003, 16:361-374.
30. Rubio G., López-Muñoz F., Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord 2006, 8:289-293.
31. Caputo F., Bernardi M. Medications acting on the GABA system in the treatment of alcoholic patients. Curr Pharm Des 2010, 16:2118-2125.
32. Le Fauve C.E., Litten R.Z., Randall C.L., et al. Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity. Alcohol Clin Exp Res 2004, 28:302-312.
33. Maremmani I., Pacini M., Lamanna F., et al. Mood stabilizers in the treatment of substance use disorders. CNS Spectr 2010, 15:95-109.
34. Johnson B.A. Medication treatment of different types of alcoholism. Am J Psychiatry 2010, 167:630-639.
35. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
36. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
37. Nierenberg A.A., Ostacher M.J., Calabrese J.R., et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol or risperidone. Am J Psychiatry 2006, 163:210-216.
38. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006, 11:227-240.
39. Kelly T., Lieberman D.Z. The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. J Affect Disord 2009, 116:222-226.
40. Oslin D.W. Treatment of late-life depression complicated by alcohol dependence. Am J Geriatr Psychiatry 2005, 13:491-500.
41. Nierenberg A.A., Husain M.M., Trivedi M.H., et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010, 40:41-50.
42. Malhi G.S., Ivanovski B., Hadzi-Pavlovic D., Mitchell P.B., Vieta E., Sachdev P. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007, 9:114-125.
43. Gopalakrishnan R., Ross J., O'Brien C., et al. Course of late-life depression with alcoholism following combination therapy. J Stud Alcohol Drugs 2009, 70:237-241.
44. Stahl S.M., Nierenberg A.A., Gorman J.M. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 2001, 62:17-23.
45. Gourion D. Antidepressants and their onset of action: a major clinical, methodological and pronostical issue. Encephale 2008, 34:73-81.
46. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999, 375:31-40.
47. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996, 29:23-26.
48. Hashimoto K. The role of glutamate on the action of antidepressant. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1558-1568.
49. Cusin C., Hilton G.Q., Nierenberg A.A. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry 2012, 169:868-869.
50. Szymkowicz S.M., Finnegan N., Dale R.M. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord 2012, 10.1016/j.jad.2012.10.015.
51. Covvey J.R., Crawford A.N., Lowe D.K. Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother 2012, 46:117-123.
52. Gosek P., Chojnacka M., Bieńkowski P., et al. Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression. Psychiatr Pol 2012, 46:283-294.
53. Correll G.E., Futter G.E. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 2006, 7:92-95.
54. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of Ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012. http://dx.doi.org/10.1016/jbiopsych.2011.12.010.
55. Diazgranados N., Ibrahim L., Brutsche N.E., et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010, 67:793-802.
56. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
57. Larkin G.L., Beautrais A.L. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011, 14:1127-1131.
58. Okamoto N., Nakai T., Sakamoto K., et al. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J ECT 2010, 26:223-227.
59. Ostroff R., Gonzales M., Sanacora G. Antidepressant effect of ketamine during ECT. Am J Psychiatry 2005, 162:1385-1386.
60. Loo C., Simpson B., MacPherson R. Augmentation strategies in electroconvulsive therapy. J ECT 2010, 26:202-207.
61. Phelps L.E., Brutsche N., Moral J.R., et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2009, 65:181-184.
62. Salvadore G., Cornwell B.R., Colon-Rosario V., et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009, 65:289-295.
63. Hill S.L., Harbon S.C., Coulson J., et al. Methoxetamine toxicity reported to the national poisons information service: clinical characteristics and patterns of enquiries (including the period of the introduction of the UK's first Temporary Class Drug Order). Emerg Med J 2013, 10.1136/emermed-2012-202251.
64. Misselbrook G.P., Hamilton E.J. Out with the old, in with the new? Case reports of the clinical features and acute management of two novel designer drugs. Acute Med 2012, 11:157-160.
65. European Monitoring Centre for Drugs and Drug Addiction. Annual report. 2012. Available on: http://www.emcdda.europa.eu/attachements.cfm/att_190854_EN_TDAC12001ENC_.pdf.
66. Casale FJ. 4-Methoxyphencyclidine: an analytical profile. 2012. Available on: http://www.justice.gov/dea/pr/microgram-journals/2011/mj8-2_39-42.pdf (visited February 11, 2013).
67. Advisory Council on the Misuse of Drugs. Methoxetamine. 2012. Available on: http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012?view=Binary (visited February 12, 2013).
68. Zarantonello P., Bettini E., Paio A., et al. Novel analogues of ketamine and phencycline as NMDA receptor antagonists. Bioorg Med Chem Lett 2011, 21:2059-2063.
69. Coppola M., Mondola M. Methoxetamine: From drug of abuse to rapid-acting antidepressant. Med Hypotheses 2012, 79:504-507.
70. Kalsi S.K., Wood D.M., Dargan P.I. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J 2011, 4:7107.
71. Douglas R.J., Martin K.A. Mapping the matrix: the ways of neocortex. Neuron 2007, 56:226-238.
72. Duman R.S., Li N., Liu R.J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant action of ketamine. Neuropharmacology 2012, 62:35-41.
73. Dwyer J.R., Duman R.S. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry 2012, 10.1016/j.biopsych.2012.11.011.
74. Monteggia L.M., Gideons E., Kavalali E.T. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 2012, 10.1016/j.biopsych.2012.09.006.
75. Autry A.E., Adachi M., Nosyreva E. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
76. Delgado P.L. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000, 61:7-11.
77. Hirschfeld R.M. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000, 61:4-6.
78. von Wolff A., Hölzel L.P., Westphal A., et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord 2013, 144:7-15.
79. Bandelow B., Sher L., Bunevicius R., Hollander E., et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 2012, 16:77-84.
80. Verdu B., Decosterd I., Buclin T., et al. Antidepressants for the treatment of chronic pain. Drugs 2008, 68:2611-2632.
81. Arias A.J., Sewell R.A. Pharmacogenetically driven treatments for alcoholism: are we there yet?. CNS Drugs 2012, 26:461-476.
82. Berrocoso E., Sanchez-Blazquez P., Garzon J., et al. Opiates as antidepressants. Curr Pharm Des 2011, 19:123-130.
83. Barber J. Examining the use of tramadol hydrochloride as an antidepressant. Exp Clin Psychopharmacol 2011, 19:123-130.
84. Garriock H.A., Tanowitz M., Kraft J.B., et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry 2010, 167:565-573.
85. Ide S., Fujiwara S., Fujiwara M., et al. Antidepressant-like effect of venlafaxine is abolished in μ-opioid receptor-knockout mice. J Pharmacol Sci 2010, 114:107-110.
86. Ide S., Sora I., Ikeda K., et al. Reduced emotional and corticosterone responses to stress in mu-opioid receptor knockout mice. Neuropharmacology 2010, 58:241-247.
87. Berrocoso E., Mico J.A. Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. Int J Neuropsychopharmacol 2009, 12:1033-1044.
88. Hayashi T., Su T.P. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004, 18:269-284.
89. Niitsu T., Iyo M., Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pharm Des 2012, 18:875-883.
90. Narita N., Hashimoto K., Tomitaka S.I., Minabe Y. Interaction of selective serotonin reuptake inhibitors with subtypes of receptors in the rat brain. Eur J Pharmacol 1996, 307:117-119.
91. Schmidt A., Lebel L., Koe B.K., Seeger T., Heym J. Sertraline potently displaces (+)-[3H]3-PPP binding to sigma-sites in rat brain. Eur J Pharmacol 1989, 165:335-336.
92. Itzhak Y., Kassim C.O. Clorgyline displays high affinity for sigma-binding sites in C57BL/6 mouse brain. Eur J Pharmacol 1990, 176:107-108.
93. Kulkarni S.K., Dhir A. Sigma-1 receptors in major depression and anxiety. Expert Rev Neurother 2009, 9:1021-1034.
94. Pande A.C., Geneve J., Scherrer B. Igmesine, a novelsigma ligand, has antidepressant properties. Int J Neuropsychopharmacol 1998, 1:S8-S9.
95. Bermack J.E., Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005 Mar, 97:317-336.
96. Ago Y., Yano K., Hiramatsu N., Takuma K., Matsuda T. Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and σ (1) receptor activation. Psychopharmacology 2011, 217:377-386.
97. Miyatake R., Furukawa A., Matsushita S., et al. Functional polymorphisms in the sigma1 receptor gene associated with alcoholism. Biol Psychiatry 2004, 55:85-90.
98. Pettinati H.M. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry 2001, 62:26-31.
99. Cornelius J.R., Salloum I.M., Ehler J.G., et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997, 54:700-705.
100. Dagyte G., Den Boer J.A., Trentani A. The cholinergic system and depression. Behav Brain Res 2011, 221:574-582.
101. Janowsky D.S., El-Yousef M.K., Davis J.M. Acethylcholine and depression. Psychosom Med 1974, 36:248-257.
102. Browne R.G. Effects of antidepressants and anticholinergics in a mouse "behavioural despair" test. Eur J Pharmacol 1979, 58:331-334.
103. Drevets W.C., Furey M.L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010, 67:432-438.
104. Furey M.L., Drevets W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006, 63:432-438.
105. Niittykoski M., Ruotsalainen S., Haapalinna A., et al. Activation of muscarinic M3-like receptors and beta-adrenoceptors, but not M2-like muscarinic receptors or alpha-adrenoceptors, directly modulates corticostriatal neurotransmission in vitro. Neuroscience 1999, 90:95-105.
106. Rawis S.M., McGinty J.F. Muscarinic receptors regulate extracellular glutamate levels in the rat striatum: an in vivo microdialysis study. J Pharmacol Exp Ther 1998, 286:91-98.
107. Hamam B.N., Sinai M., Poirier G., et al. Cholinergic suppression of excitatory synaptic responses in layer II of the medial entorhinal cortex. Hippocampus 2007, 17:103-113.
108. Gulledge A.T., Bucci D.J., Zhang S.S., et al. M1 receptors mediate cholinergic modulation of excitability in neocortical pyramidal neurons. J Neurosci 2009, 29:9888-9902.
109. Jo J., Son G.H., Winters B.L., et al. Muscarinic receptors induce LTD of NMDAR EPSCs via a mechanism involving hippocalcin, AP2 and PSD-95. Nat Neurosci 2010, 13:1216-1224.
110. Amar M., Lucas-Meunier E., Baux G., et al. Blockade of different muscarinic receptors subtype changes the equilibrium between excitation and inhibition in rat visual cortex. Neuroscience 2010, 169:1610-1620.
111. Wang J.C., Hinrichs A.L., Stock H., et al. Evidence of common and specific genetic effects: association of the muscarinic acethylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet 2004, 13:1903-1911.
112. Comings D.E., Wu S., Rostamkhani M., McGue M., Iacono W.G., MacMurray J.P. Association of the muscarinic cholinergic 2 receptor (CHMR2) gene with major depression in women. Am J Med Genet 2002, 114:527-529.
113. Scarr E. Muscarinic receptors in psychiatric disorders-can we mimic'health'?. Neurosignals 2009, 17:298-310.
114. Schulte T., Mũller-Oehring E.M., Pfefferbaum A., et al. Neurocircuitry of emotion and cognition in alcoholism: contributions from white matter fiber tractography. Dialogues Clin Neurosci 2010, 12:554-560.
115. Hauser S.R., Getachew B., Taylor R.E., et al. Alcohol induced depressive-like behavior is associated with a reduction in hippocampal BDNF. Pharmacol Biochem Behav 2011, 100:253-258.
116. Sher L. Risk and protective factors for suicide in patients with alcoholism. ScientificWorldJournal 2006, 6:1405-1411.
117. Murrough J.W. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther 2012, 91:303-309.